| 1 |
33376542 | Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells. | 2021 Feb |
1 |
| 2 |
33609728 | Evaluation of Virola oleifera activity in musculoskeletal pathologies: Inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib. | 2021 May 23 |
1 |
| 3 |
33868466 | Effects of a combined therapy of bortezomib and ionizing radiation on chondrosarcoma three-dimensional spheroid cultures. | 2021 Jun |
2 |
| 4 |
32551032 | BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis. | 2020 |
1 |
| 5 |
32839432 | The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. | 2020 Aug 24 |
2 |
| 6 |
31322176 | Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27. | 2019 Sep |
1 |
| 7 |
31406244 | FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma. | 2019 Oct |
2 |
| 8 |
29291406 | BaxΔ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death. | 2018 Jan 29 |
1 |
| 9 |
30292410 | Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. | 2018 Nov 2 |
1 |
| 10 |
28912868 | Bax is involved in the anticancer activity of Velcade in colorectal cancer. | 2017 Oct |
1 |
| 11 |
26956626 | Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. | 2016 Mar 9 |
1 |
| 12 |
27769058 | Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. | 2016 Nov 22 |
1 |
| 13 |
25602436 | Bortezomib inhibits gastric carcinoma HGC-27 cells through the phospho-Jun N-terminal kinase (p-JNK) pathway in vitro. | 2015 Apr 1 |
1 |
| 14 |
25975837 | ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. | 2015 Sep |
1 |
| 15 |
25995634 | Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells. | 2015 |
1 |
| 16 |
24486574 | Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. | 2014 Mar 15 |
1 |
| 17 |
22086447 | Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. | 2013 Feb |
1 |
| 18 |
23179179 | TRAIL promotes membrane blebbing, detachment and migration of cells displaying a dysfunctional intrinsic pathway of apoptosis. | 2013 Mar |
1 |
| 19 |
23481040 | p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells. | 2013 Jun |
1 |
| 20 |
22393246 | ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. | 2012 Jun |
2 |
| 21 |
23226303 | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. | 2012 |
1 |
| 22 |
23300762 | Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. | 2012 |
1 |
| 23 |
21459798 | Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. | 2011 May 15 |
1 |
| 24 |
21729550 | [Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism]. | 2011 Jun |
1 |
| 25 |
22169296 | [Mechanism associated to enhancing the sensitivity of myeloma cells U266 to bortezomib by 2-methoxyestradiol]. | 2011 Dec |
1 |
| 26 |
19894220 | Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. | 2010 Jul 1 |
1 |
| 27 |
19960346 | Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. | 2010 Aug |
1 |
| 28 |
20383943 | Bortezomib induces apoptosis in human neuroblastoma CHP126 cells. | 2010 Mar |
2 |
| 29 |
20850924 | MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. | 2010 Dec 28 |
1 |
| 30 |
21472287 | Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. | 2010 Jul-Aug |
1 |
| 31 |
19270531 | Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. | 2009 May |
1 |
| 32 |
18160669 | Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. | 2008 Mar 1 |
3 |
| 33 |
18357392 | Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines. | 2008 Apr |
3 |
| 34 |
18445700 | Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. | 2008 Jun |
4 |
| 35 |
18928586 | [Inducing-apoptosis effect of bortezomib on acute monocytic leukemia cell SHI-1 and its influence on expressions of Bcl2l12, Bcl-2 and Bax genes]. | 2008 Oct |
2 |
| 36 |
17308121 | Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. | 2007 Feb 15 |
1 |
| 37 |
17374988 | Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. | 2007 Apr |
1 |
| 38 |
17545623 | Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. | 2007 Jun 1 |
1 |
| 39 |
17912641 | Absence of Bax switched MG132-induced apoptosis to non-apoptotic cell death that could be suppressed by transcriptional or translational inhibition. | 2007 Dec |
1 |
| 40 |
16166592 | The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. | 2006 Jan 1 |
1 |
| 41 |
16219794 | Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. | 2006 Mar 15 |
1 |
| 42 |
16424655 | Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. | 2006 |
3 |
| 43 |
17018621 | Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. | 2006 Oct 1 |
1 |
| 44 |
15929791 | Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. | 2005 Jun 1 |
1 |
| 45 |
16178003 | Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. | 2005 Nov 1 |
1 |
| 46 |
16382051 | The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. | 2005 Nov |
1 |
| 47 |
15131062 | Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. | 2004 May 1 |
1 |
| 48 |
15638966 | Use of proteasome inhibition in the treatment of lung cancer. | 2004 Dec |
1 |
| 49 |
12902978 | The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. | 2003 Aug 7 |
1 |
| 50 |
14513055 | The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. | 2003 Oct |
1 |